التفاصيل البيبلوغرافية
العنوان: |
D-dimer for efficacy prediction in COVID-19 patients treated with paxlovid |
المؤلفون: |
Daishi Li, Qingrong Wu, Wenrui Lin, Yanli Xie, Furong Zeng |
المصدر: |
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-7 (2024) |
بيانات النشر: |
BMC, 2024. |
سنة النشر: |
2024 |
المجموعة: |
LCC:Infectious and parasitic diseases |
مصطلحات موضوعية: |
COVID-19, Paxlovid, D-dimer, Efficacy prediction, Composite disease progression outcome, Infectious and parasitic diseases, RC109-216 |
الوصف: |
Abstract Background Paxlovid is one of the most effective antiviral therapies for COVID-19 patients, but no studies have explored the efficacy predictors of this drug. Methods To investigate whether D-dimer could be used as a predictor of paxlovid response. Our study included 394 patients diagnosed with COVID-19 who were treated with paxlovid at Xiangya Hospital from Dec 5, 2022, to Jan 31, 2023. We analyzed the composite outcome and all-cause mortality and compared the clinical and demographic data of patients with normal and abnormal D-dimer levels. Results We found that 324 patients (82.2%) with D-dimer levels were regularly compared with 70 patients (17.8%). Compared with patients with normal D-dimer levels, those with elevated D-dimer levels exhibited significantly reduced albumin levels, along with elevated levels of white blood cells, platelets, neutrophils, blood urea nitrogen, and procalcitonin. Kaplan–Meier survival curves showed that patients displaying increased D-dimer levels demonstrated a significantly higher incidence of composite disease progression within 28 days (p = 0.002) and all-cause death (p |
نوع الوثيقة: |
article |
وصف الملف: |
electronic resource |
اللغة: |
English |
تدمد: |
1471-2334 |
Relation: |
https://doaj.org/toc/1471-2334 |
DOI: |
10.1186/s12879-024-10254-x |
URL الوصول: |
https://doaj.org/article/513b7def0f5247628818b81ec0d65ca5 |
رقم الانضمام: |
edsdoj.513b7def0f5247628818b81ec0d65ca5 |
قاعدة البيانات: |
Directory of Open Access Journals |